| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| Cost of Revenue | $0 | — | — |
| Gross Profit | $0 | — | — |
| R&D Expense | $162K | +1568.9% | — |
| SG&A Expense | $20K | +91.3% | +160.4% |
| Operating Income | -$182K | -802.5% | -2268.8% |
| Net Income | -$186K | -5.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $229 | +1.3% | -94.9% |
| Current Assets | $229 | +1.3% | -94.9% |
| Total Assets | $229 | +1.3% | -94.9% |
| Current Liabilities | $694K | +13.1% | +24.6% |
| Total Liabilities | $694K | +13.1% | +24.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$50K | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $48K | — | — |
| -900.9% |
| EPS (Basic) | $0.00 | — | — |
| -$694K |
| -13.1% |
| -25.6% |